InfectionEmergencyICD-10 B00.0

Eczema herpeticum & cutaneous HSV

Kaposi varicelliform eruption ยท disseminated HSV ยท widespread herpes simplex

Eczema herpeticum (Kaposi varicelliform eruption) is a disseminated cutaneous herpes simplex virus (HSV-1 > HSV-2) infection superimposed on a disrupted skin barrier โ€” most often atopic eczema, but also Darier disease, pemphigus, burn injury, pityriasis rubra pilaris, ichthyosis, mycosis fungoides, post-Mohs / large-defect reconstruction, and ICI-related dermatitis. It is a dermatological emergency requiring early antiviral therapy. Recognition matters in skin-oncology because both ICI-induced eczema and post-surgical denuded skin are predisposing settings.

CurrentLast reviewed 16 May 2026
Clinical image of Eczema herpeticum & cutaneous HSV
Eczema herpeticum & cutaneous HSV. Image sourced from DermNet New Zealand. Used under CC BY-NC-ND 4.0. No endorsement implied.

Context and risk factors

  • Most common predisposition: atopic eczema.
  • Other underlying conditions:
    • Darier disease, Hailey-Hailey, pemphigus, bullous pemphigoid, pityriasis rubra pilaris, ichthyosis.
    • Burns, large surgical defects, post-grafting wounds.
    • Mycosis fungoides, cutaneous T-cell lymphoma.
    • ICI-related dermatitis, eczema flares on EGFRi / BRAFi.
    • Immunosuppression โ€” transplant, HIV.
  • HSV-1 > HSV-2; reactivation or primary infection.

Clinical features

  • Abrupt onset crops of monomorphic 2-3 mm umbilicated vesicopustules on existing dermatosis, often face / neck / trunk.
  • Punched-out erosions and haemorrhagic crusts after vesicle rupture.
  • Pain rather than itch may predominate.
  • Systemic features: fever, malaise, lymphadenopathy, sometimes sepsis.
  • Severe forms: keratoconjunctivitis, encephalitis, hepatitis, disseminated intravascular coagulation.
  • Differentiate from typical eczema flare (vesicles + punched-out erosions, not background lichenification only).

Investigations

  • HSV PCR from vesicle / erosion swab โ€” sensitive and specific; results within hours.
  • Tzanck smear (multinucleated giant cells; doesn't distinguish HSV vs VZV).
  • Bacterial swab โ€” secondary S. aureus infection common; eczema herpeticum + impetigo coexistence frequent.
  • Bloods if systemic features: FBC, LFT, U&E, CRP, blood cultures; consider HIV.
  • Ophthalmology review if periocular involvement.

Differentials

  • Bullous impetigo / staphylococcal scalded skin โ€” staphylococcal exotoxin; large fragile bullae.
  • Varicella / disseminated zoster โ€” pleomorphic vs monomorphic vesicles.
  • Hand-foot-and-mouth disease (Coxsackie).
  • Smallpox / monkeypox in atypical / travel-related cases.
  • Disseminated CMV / EBV in immunosuppressed.
  • SJS/TEN โ€” drug history; mucosal involvement.
  • Eczema flare with crusting โ€” no punched-out erosions or vesicles.

Management

  • Empirical antiviral while awaiting PCR โ€” do not delay:
    • Aciclovir 400-800 mg PO 5ร— daily for 5-7 days.
    • Valaciclovir 1 g PO BD until lesions heal (typically 10โ€“14 days).
    • IV aciclovir 5-10 mg/kg TDS in severe / systemic / paediatric / immunosuppressed / ocular involvement / no oral tolerance.
  • Hold topical calcineurin inhibitors and tapering of high-potency topical steroids until infection controlled.
  • Bland emollients; eczema management resumes once infection controlled.
  • Treat coexistent bacterial superinfection (flucloxacillin / co-amoxiclav).
  • Admit if systemic features, ocular involvement, immunosuppression, paediatric, or significant body-surface area.
  • Education re recognition (early antiviral course at home for recurrent disease in atopic patients).
  • Long-term suppressive aciclovir (400 mg BD) in recurrent disease.
  • Skin-oncology specifics:
    • ICI dermatitis with eczematous appearance: do not start TCI in suspected EH; PCR first.
    • Post-Mohs / post-graft denuded skin: empirical antiviral if widespread vesicles; multidisciplinary discussion.

References

  1. Wollenberg A et al. Eczema herpeticum and other dermatoses complicated by herpes simplex virus infection. J Allergy Clin Immunol. 2003;112:667-674.
  2. Aronson PL et al. Risk factors for severe disease in eczema herpeticum. J Pediatr. 2014;164:1131-1136.
  3. Beck LA, Boguniewicz M, Hata T, et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol. 2009;124:260-269.
  4. NICE CKS. Atopic eczema โ€” herpes simplex infection. London: NICE; accessed 18 May 2026.

Spot a correction?

If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.